MoonLake Immunotherapeutics Shares Climb Roughly 8% Ahead of FDA Filing Deadline
MoonLake Immunotherapeutics shares rose roughly 8% on Wednesday as investors focused on an upcoming FDA acceptance deadline for its lead drug filing, sonelokimab.
Shares of MoonLake Immunotherapeutics (MLTX) climbed roughly 8% on Wednesday, continuing this week's positive sentiment as investors focused on a near-term regulatory milestone for its lead drug, sonelokimab.MoonLake is developing Sonelokimab primarily for hidradenitis suppurativa (HS), a chronic i…